New lipid therapies: PCSK9 inhibitors
Journal of Clinical and Translational Endocrinology: Case Reports · 2016
DOI: 10.1016/j.jecr.2016.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Translational Endocrinology: Case Reports, 2016. Verfasst von Farah Meah und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prevention clinical situations in addition to lifestyle modifications. Low density lipoprotein cholesterol (LDL-C) is a key mediator of atherogenesis. Most cholesterol guidelines propose specific LDL-C while recently the ACC/AHA recommends statin therapy without a specific LDL-C target. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease that leads to LDL receptor degradation. The decreased availability of LDL receptors results in decreased clearance and an increase of circulating LDL-C particles. Monoclonal antibodies that inhibit PCSK9 (PCSK9 abs) reduce LDL-C levels and may be especially helpful in familial hypercholesterolemia and statin-intolerant patients. PCSK9 inhibition is an exciting and promising new therapy for protection against macrovascular events.
Zitieren
APA
Meah, F., Basit, A., Mazhari, A., Emanuele, M. A., & Emanuele, N. (2016). New lipid therapies: PCSK9 inhibitors. Journal of Clinical and Translational Endocrinology: Case Reports. https://doi.org/10.1016/j.jecr.2016.07.001
Vancouver
Meah F, Basit A, Mazhari A, Emanuele MA, Emanuele N. New lipid therapies: PCSK9 inhibitors. Journal of Clinical and Translational Endocrinology: Case Reports. 2016. doi:10.1016/j.jecr.2016.07.001
BibTeX
@article{Meah2016,
author = {Meah, Farah and Basit, Arshi and Mazhari, Alaleh and Emanuele, Mary Ann and Emanuele, Nicholas},
title = {New lipid therapies: PCSK9 inhibitors},
journal = {Journal of Clinical and Translational Endocrinology: Case Reports},
year = {2016},
doi = {10.1016/j.jecr.2016.07.001}
}
EUVIMED